方法：选取我院2012-09/2016-09就诊实施TICL植入术治疗的高度近视及散光患者90例178眼，对比术前和术后3、 9mo的UCVA、BCVA、屈光度、散光值、角膜内皮细胞数、眼压和拱高值。

结果：患者术后3、 9mo UCVA和BCVA均高于术前，差异有统计学意义(P<0.05)。术后3mo屈光度(-0.52±0.23D)和散光值(-0.39±0.23D)与术后9mo的屈光度(-0.54±0.16D)和散光值(-0.33±0.56D)对比，差异均无统计学意义(P>0.05)。术后3、9mo的角膜内皮细胞数分别与术前相比，差异有统计学意义(P<0.05)。术后3、9mo眼压与术前相比，均无统计学差异(P>0.05)。

结论：TICL植入术治疗高度近视及散光患者疗效显著且安全可靠。

METHODS: Totally 90 patients(178 eyes)diagnosed as this disease were selected in our hospital during September 2012 to September 2016 by the method of random. The UCVA, BCVA, refraction, astigmatism coefficient, corneal endothelial cell, intraocular pressure, manifest refraction examination were accessed and compared before and after 3 and 9mo of surgery.

RESULTS: After 3 and 9mo of the surgery, the UCVA and BCVA were much higher than those before treatment, which the difference was statistically significant(P<0.05). We compared the refraction at 3mo(-0.52±0.23D)and 9mo(-0.54±0.16D), the astigmatism coefficient at 3mo(-0.39±0.23D)and 9mo(-0.33±0.56D)after treatment, and we found that the differences were not statistically significant(P>0.05). The corneal endothelial cells at 3 and 9mo after operation were compared with those of before treatment, and we found that the differences were statistically significant(P<0.05). The intraocular pressure of 3 and 9mo after operation was compared with that before operation, and we found that the differences were not statistically significant(P>0.05).

CONCLUSION: TICL implantation in the treatment of patients with high myopia and myopic astigmatism has a more obvious clinical efficacy and safety and reliability.